Zynerba Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ZYNE Zynerba Pharmaceuticals Inc
PDO PIMCO Dynamic Income Opportunities Fund
BOCT Innovator U.S. Equity Buffer ETF™ October
BAC Bank of America Corp
YARIY Yara International ASA
XOM Exxon Mobil Corp
XLF Financial Select Sector SPDR® Fund
XFLT XAI Octagon Floating Rate & Alternative Income Term Trust
WPC WP Carey Inc

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. It is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

CGI (GIB) Benefits From Expanding Clientele, Partner Base

9:50 am ET September 18, 2023 (Zacks) Print

CGI GIB is benefiting from an expanding clientele and strong partner base. Shares have returned 20.6%, outperforming the Zacks Computer-Services industry’s 10.4%, on a year-to-date basis. However, it has underperformed the Zacks Computer & Technology sector’s return of 36.9%.

CGI has been benefiting from strong demand for its business solutions. In the fiscal third quarter, the overall IP portfolio grew 12.4% year over year or 7.7% at constant currency. The number of consultants and professionals increased year over year by 3K, totaling 91,500 worldwide.

Expanding clientele has been a key catalyst. CGI’s solutions were selected by the likes of the U.S. Environmental Protection Agency, and Bankgirot (Sweden’s payments clearinghouse), a government ministry in Germany.

CGI also expanded its footprint in the financial services sector as it signed 28 agreements with clients in the United States, Canada, UK and Australia. The company’s All Payments solution has recently been selected by Scotiabank, a leading Canadian multinational bank.

CGI’s cloud-proven enterprise payments platform will support Scotiabank’s innovative advances in payment solutions for its global client base. CGI All Payments is used by financial services clients across the world and supports multiple currencies, languages and payment channels.

CGI Group, Inc. Price and Consensus

CGI Group, Inc. Price and Consensus

CGI Group, Inc. price-consensus-chart | CGI Group, Inc. Quote

CGI recently inked a partnership with Alimentation Couche-Tard worth C$380 million to deliver managed IT services. As part of the ten-year partnership, CGI will deliver a comprehensive range of IT services and infrastructure support for the mission-critical business functions of Couche-Tard.

Alimentation Couche-Tard, which is a multinational operator of convenience stores in Canada, will leverage the partnership to improve services to its customers.

CGI’s Prospects Bright in 2023

CGI is expected to benefit from the ongoing digitalization amid challenging macroeconomic conditions. Strong demand for the company’s managed services and IP offerings is expected to drive top-line growth in the near term.

The company’s managed services pipeline for industries like manufacturing, retail, and energy and utilities is up more than 33% for the next year, while the IP pipeline is up 30%. Moreover, in government health care and insurance, CGI’s pipeline remains well balanced across consulting system integration and managed services and is up 20% year over year.

CGI is also investing in the development of AI-based solutions and services and plans to invest $1 billion over the next three years.

The Zacks Consensus Estimate for fiscal 2023 and fiscal 2024 revenues are pegged at $10.93 billion and $11.4 billion, indicating growth of 8.42% and 4.36%, respectively.

Zacks Rank & Stocks to Consider

CGI currently has a Zacks Rank #3 (Hold).

Dell Technologies DELL, NVIDIA NVDA and Splunk SPLK are some better-ranked stocks in the broader sector, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The long-term earnings growth rate for Dell Technologies, NVIDIA and Splunk is currently pegged at 12%, 13.5% and 24.71%, respectively.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Dell Technologies Inc. (DELL): Free Stock Analysis Report
NVIDIA Corporation (NVDA): Free Stock Analysis Report
CGI Group, Inc. (GIB): Free Stock Analysis Report
Splunk Inc. (SPLK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.